GeneOne Life Science, Inc. (KRX: 011000)
South Korea
· Delayed Price · Currency is KRW 1,995.00
-35.00 (-1.72%)
Dec 20, 2024, 3:30 PM KST
GeneOne Life Science Cash Flow Statement
Financials in millions KRW. Fiscal year is January - December.
Millions KRW. Fiscal year is Jan - Dec.
Fiscal Year | TTM | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | 2018 - 2014 |
|---|---|---|---|---|---|---|---|
Period Ending | Sep '24 Sep 30, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 | Dec '20 Dec 31, 2020 | Dec '19 Dec 31, 2019 | 2018 - 2014 |
| Net Income | -72,691 | -77,768 | -38,150 | -15,888 | -18,648 | -7,619 | Upgrade
|
| Depreciation & Amortization | 17,532 | 12,776 | 5,424 | 4,650 | 4,021 | 3,420 | Upgrade
|
| Loss (Gain) From Sale of Assets | -1.73 | -3.4 | -1.31 | 106.64 | - | - | Upgrade
|
| Asset Writedown & Restructuring Costs | 32,309 | 32,309 | - | - | - | 0.5 | Upgrade
|
| Provision & Write-off of Bad Debts | 307.8 | -845.52 | 1,293 | 111.17 | -174.13 | -287.95 | Upgrade
|
| Other Operating Activities | 2,741 | 3,171 | 3,579 | -2,084 | 1,219 | 3,458 | Upgrade
|
| Change in Accounts Receivable | 1,586 | 4,835 | -2,848 | 68.06 | 1,672 | -2,223 | Upgrade
|
| Change in Inventory | -826.36 | -207.63 | -4,256 | -2,415 | 409.55 | -933.07 | Upgrade
|
| Change in Accounts Payable | 4,104 | 3,801 | -10,003 | 10,610 | 4,529 | 747.34 | Upgrade
|
| Change in Income Taxes | -20.14 | - | - | -97.74 | -67.04 | -25.22 | Upgrade
|
| Change in Other Net Operating Assets | -4,559 | 188.33 | 20,850 | -194.83 | -8,908 | 2,206 | Upgrade
|
| Operating Cash Flow | -19,529 | -21,744 | -24,113 | -4,849 | -15,916 | -1,270 | Upgrade
|
| Capital Expenditures | -4,591 | -5,601 | -45,306 | -82,442 | -16,153 | -2,837 | Upgrade
|
| Sale of Property, Plant & Equipment | 1.73 | 15.7 | - | 29.13 | - | - | Upgrade
|
| Sale (Purchase) of Intangibles | -69.78 | -51.59 | -101.81 | -75.24 | -216.6 | -172.73 | Upgrade
|
| Investment in Securities | 4,055 | 31,529 | 53,000 | -57,000 | -27,536 | 13,535 | Upgrade
|
| Other Investing Activities | 14.04 | -0 | -151.33 | -5,961 | - | 0 | Upgrade
|
| Investing Cash Flow | -590.67 | 25,892 | 8,055 | -146,398 | -44,305 | 10,471 | Upgrade
|
| Short-Term Debt Issued | - | 3,792 | 701.15 | 1,054 | - | 100 | Upgrade
|
| Long-Term Debt Issued | - | 6,271 | 11,469 | - | 23,520 | - | Upgrade
|
| Total Debt Issued | 15,339 | 10,063 | 12,171 | 1,054 | 23,520 | 100 | Upgrade
|
| Short-Term Debt Repaid | - | -2,100 | - | -150.86 | -958.08 | -163.79 | Upgrade
|
| Long-Term Debt Repaid | - | -18,712 | -5,537 | -1,639 | -10,731 | -3,536 | Upgrade
|
| Total Debt Repaid | -4,753 | -20,812 | -5,537 | -1,790 | -11,689 | -3,700 | Upgrade
|
| Net Debt Issued (Repaid) | 10,586 | -10,749 | 6,633 | -735.35 | 11,831 | -3,600 | Upgrade
|
| Issuance of Common Stock | 3,590 | 2,470 | 382.44 | 112,609 | 94,404 | 2,944 | Upgrade
|
| Other Financing Activities | 0 | -5.64 | -2.97 | -849.86 | - | -0.86 | Upgrade
|
| Financing Cash Flow | 14,176 | -8,285 | 7,013 | 111,023 | 106,235 | -657 | Upgrade
|
| Foreign Exchange Rate Adjustments | -20.55 | -13.29 | -3.42 | 101.37 | -503.35 | -0.63 | Upgrade
|
| Miscellaneous Cash Flow Adjustments | -0 | - | 0 | 0 | 0 | 0 | Upgrade
|
| Net Cash Flow | -5,965 | -4,150 | -9,049 | -40,122 | 45,510 | 8,543 | Upgrade
|
| Free Cash Flow | -24,121 | -27,345 | -69,419 | -87,291 | -32,069 | -4,107 | Upgrade
|
| Free Cash Flow Margin | -63.53% | -68.02% | -142.49% | -225.56% | -77.27% | -9.96% | Upgrade
|
| Free Cash Flow Per Share | -305.08 | -351.70 | -895.90 | -1175.77 | -531.20 | -127.91 | Upgrade
|
| Cash Interest Paid | 84.33 | 82.15 | 58.5 | - | 48.96 | 243.62 | Upgrade
|
| Cash Income Tax Paid | 192.84 | 104.9 | 326.55 | 189.71 | - | - | Upgrade
|
| Levered Free Cash Flow | -13,240 | -22,581 | -73,691 | -103,116 | -13,891 | -5,597 | Upgrade
|
| Unlevered Free Cash Flow | -12,255 | -21,843 | -69,123 | -100,332 | -13,498 | -4,368 | Upgrade
|
| Change in Net Working Capital | -2,655 | -1,263 | 4,014 | 5,259 | -10,432 | -387.8 | Upgrade
|
Source: S&P Capital IQ. Standard template. Financial Sources.